<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34531277</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1399-3003</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur Respir J</ISOAbbreviation></Journal><ArticleTitle>Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2102245</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/13993003.02245-2021</ELocationID><Abstract><AbstractText><b>Long COVID was detected in both adults and children and is characterised by immunological dysregulation. Autoimmune reactions in adult patients and allergic reactions in children appear to be critical factors.</b> https://bit.ly/38RfSyT</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortona</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Gender-Specific Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malorni</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Global Health, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy Walter.Malorni@unicatt.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur Respir J. 2022 Feb 3;59(2):2101341. doi: 10.1183/13993003.01341-2021</RefSource><PMID Version="1">34210789</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText>Around a quarter of people who have had coronavirus disease 2019 (COVID-19) experience symptoms that continue for at least 1 month, but one in ten are still unwell after 12&#x2005;weeks. This very debilitating condition has been defined by patient groups as &#x201c;long COVID&#x201d;, elsewhere called post-COVID, whereas the patients are frequently called COVID-19 long-haulers [1]. Long COVID has a serious impact on patient ability to go back to work or school, to have a social life and may have significant economic consequences for patients, their families and for society. The condition is characterised by long-term sequelae and can involve a range of about 200 different and overlapping symptoms, such as persistent fatigue, chest and muscle pain, headache, shortness of breath, anosmia, muscle weakness, fever, cognitive dysfunction (brain fog), tachycardia, intestinal disorders and skin manifestations. It can affect anyone, but women appear to be twice as likely to develop long COVID as men, but only until around age 60 years, when the risk level becomes similar [2&#x2013;4].</AbstractText></OtherAbstract><CoiStatement>Conflicts of interest: The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34531277</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pii">13993003.02245-2021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yelin D, Wirtheim E, Vetter P, et al. . Long-term consequences of COVID-19: research needs. Lancet Infect Dis 2020; 20: 1115&#x2013;1117. doi:10.1016/S1473-3099(20)30701-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27: 626&#x2013;631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, et al. . Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health 2021; 18: 2621. doi:10.3390/ijerph18052621</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Rayner C, Delaney B. Fresh evidence of the scale and scope of long COVID. BMJ 2021; 373: n853. doi:10.1136/bmj.n853</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n853</ArticleId><ArticleId IdType="pubmed">33795224</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanov IM, Spiridonova E, Bobkova P, et al. . Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J 2022; 59: 2101341. doi:10.1183/13993003.01341-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01341-2021</ArticleId><ArticleId IdType="pmc">PMC8576804</ArticleId><ArticleId IdType="pubmed">34210789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Munblit D, De Rose C, et al. . Preliminary evidence on long COVID in children. Acta Paediatr 2021; 110: 2208&#x2013;2211. doi:10.1111/apa.15870</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15870</ArticleId><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Say D, Crawford N, McNab S, et al. . Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health 2021; 5: 22&#x2013;23. doi:10.1016/S2352-4642(21)00124-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00124-3</ArticleId><ArticleId IdType="pmc">PMC8057863</ArticleId><ArticleId IdType="pubmed">33891880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot X, Ribera A, Gasque P. Chikungunya-induced arthritis in Reunion Island: a long-term observational follow-up study showing frequently persistent joint symptoms, some cases of persistent chikungunya immunoglobulin M positivity, and no anticyclic citrullinated peptide seroconversion after 13 years. J Infect Dis 2020; 222: 1740&#x2013;1744. doi:10.1093/infdis/jiaa261</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa261</ArticleId><ArticleId IdType="pubmed">32428203</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DV, Kibuuka H, Millard M, et al. . Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015; 15: 905&#x2013;912. doi:10.1016/S1473-3099(15)70152-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70152-0</ArticleId><ArticleId IdType="pubmed">25910637</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169. doi:10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, et al. . Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation. Pathogens 2021; 10: 763. doi:10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ero&#x11f;lu &#x130;, Ero&#x11f;lu B&#xc7;, G&#xfc;ven GS. Altered tryptophan absorption and metabolism could underlie long-term symptoms in survivors of coronavirus disease 2019 (COVID-19). Nutrition 2021; 90: 111308. doi:10.1016/j.nut.2021.111308</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2021.111308</ArticleId><ArticleId IdType="pmc">PMC8087860</ArticleId><ArticleId IdType="pubmed">34111831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen NC, Papies J, Bajaj T, et al. . SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun 2021; 12: 3818. doi:10.1038/s41467-021-24007-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24007-w</ArticleId><ArticleId IdType="pmc">PMC8217552</ArticleId><ArticleId IdType="pubmed">34155207</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC Global COVID-19 Paediatric Follow-Up Working Group. ISARIC Global COVID-19 paediatric follow-up. 2021. https://isaric.org/research/covid-19-clinical-research-resources/paediatric-follow-up</Citation></Reference><Reference><Citation>Buonsenso D, Di Giuda D, Sigfrid L, et al. . Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Health 2021; 5: 677&#x2013;680. doi:10.1016/S2352-4642(21)00196-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00196-6</ArticleId><ArticleId IdType="pmc">PMC8324416</ArticleId><ArticleId IdType="pubmed">34339624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis ML, Maselli A, Pagano MT, et al. . Immune response and autoimmune diseases: a matter of sex. Ital J Gender Specific Med 2019; 5: 11&#x2013;20.</Citation></Reference><Reference><Citation>Klein S, Flanagan K. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626&#x2013;638. doi:10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarefors S, Bennet L, You E, et al. . Lyme borreliosis reinfection: might it be explained by a gender difference in immune response? Immunology 2006; 118: 224&#x2013;232. doi:10.1111/j.1365-2567.2006.02360.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2006.02360.x</ArticleId><ArticleId IdType="pmc">PMC1782288</ArticleId><ArticleId IdType="pubmed">16771857</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadakedath S, Kandi V, Mohapatra RK, et al. . Immunological aspects and gender bias during respiratory viral infections including novel coronavirus disease-19 (COVID-19): a scoping review. J Med Virol 2021; 93: 5295&#x2013;5309. doi:10.1002/jmv.27081</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27081</ArticleId><ArticleId IdType="pmc">PMC8242919</ArticleId><ArticleId IdType="pubmed">33990972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Buonsenso D, Carfi A, et al. . Long COVID: an estrogen-associated autoimmune disease? Cell Death Discov 2021; 7: 77. doi:10.1038/s41420-021-00464-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00464-6</ArticleId><ArticleId IdType="pmc">PMC8042352</ArticleId><ArticleId IdType="pubmed">33850105</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature 2021; 590: 29&#x2013;31. doi:10.1038/d41586-021-00149-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00149-1</ArticleId><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature 2021; 595: 283&#x2013;288. doi:10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, et al. . The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20: 102792. doi:10.1016/j.autrev.2021.102792</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>